News | February 28, 2026
Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
